Compare KD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | NRIX |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2021 | 2020 |
| Metric | KD | NRIX |
|---|---|---|
| Price | $13.30 | $25.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $25.92 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 3.6M | 963.9K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,092,000,000.00 | $76,987,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $0.08 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.23 | ★ 99.31 |
| 52 Week Low | $10.10 | $8.20 |
| 52 Week High | $33.90 | $28.23 |
| Indicator | KD | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 44.71 |
| Support Level | $13.14 | $14.63 |
| Resistance Level | $13.81 | $24.98 |
| Average True Range (ATR) | 0.54 | 0.94 |
| MACD | 0.01 | -0.35 |
| Stochastic Oscillator | 76.09 | 0.91 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.